CNR2 and Alzheimer disease: Specifically, transgenic CB2 knockout mice had significantly decreased Amyloid-β-enriched plaque density in the hippocampus, as measured with Methoxy-XO4 staining, and improved cognitive and learning deficits in mouse models of Alzheimer’s disease-like pathology [47, 48].